Aage kya plan hai Sudarshan Pharma ka?
Toh bhai, Sudarshan Pharma ke Directors May 22, 2026 ko ek important meeting karne wale hain. Is meeting ka sabse bada agenda hai unke shares ko BSE SME platform se hata kar BSE aur NSE ke main trading board par shift karna. Iske liye May 18, 2026 tak sabhi related communications ho jayengi.
Yeh move kyun important hai?
Company yeh sab isliye kar rahi hai taaki unka market mein presence badhe aur shares ki trading aasan ho jaaye (liquidity improve ho). SME platform se main board par aana ekdum bada step hota hai, matlab company ab aur mature ho gayi hai aur zyada investors tak pahunchna chahti hai. Isse unki visibility badhegi aur future mein funding bhi easily mil sakti hai.
Shareholders ka kya scene hai?
Yeh migration tabhi ho payegi jab company ke shareholders approve karein. Iske liye Sudarshan Pharma postal ballot ke through unka approval bhi lega. Toh yeh shareholders ka nod milna bohot zaruri hai.
Risk kya ho sakta hai?
Is poore process mein kuch risks bhi hain. Sabse pehla toh shareholders ka approval milna, dusra BSE aur NSE ke main board ke listing rules ko follow karna thoda tricky ho sakta hai. Agar koi approval nahi mila ya der hui toh yeh plan postpone ho sakta hai.
Aage kya track karna hai?
Investors ko ab May 22, 2026 ko hone wali board meeting ke result par nazar rakhni hogi. Uske baad shareholders ke approval ki announcement aur BSE/NSE mein application submit hone ka wait karna padega. Regulatory approvals kaise milte hain, yeh bhi dekhna hoga.